By P.A. Voûte, Ann Barrett, Michael C.G. Stevens, Hubert N. Caron
"Cancer in teenagers" introduces paediatric oncology in a transparent and concise method, overlaying all of the attainable issues which can come up in the course of remedy and a number of the results of the sickness. even though early life melanoma is unusual, accounting for only 1% of all melanoma in industrialized nations, it really is one in every of nice clinical curiosity for a few purposes. different types of melanoma are almost special to youth, while the carcinomas most often noticeable in adults are tremendous infrequent between youngsters. essentially the most notable growth in melanoma therapy has been made in paediatric oncology. research of adolescence tumours has ended in significant advances within the figuring out of the genetic aetiology of melanoma. "Cancer in teenagers" brings jointly a world team of hugely revered editors and individuals who offer evidence-based info on easy methods to examine and deal with the typical cancers in early life. cutting-edge descriptions of what's uncomplicated and crucial for administration are integrated; there are new chapters overlaying destiny developments in melanoma chemotherapy, surgical procedure, palliative care, myeloid leukaemia, and malignant mesenchymal tumours; new editors, and plenty of new members. geared toward paediatric oncologists, trainees in oncology and paediatrics, this booklet also will attract paediatric nurses, melanoma nurses, and paramedical paediatric employees.
Read Online or Download Cancer in Children: Clinical Management (Oxford Medical Publications) PDF
Similar pediatrics books
A big and functional advisor at the felony and moral features of kid wellbeing and fitness care that allows nurses to appreciate the felony and moral rules that underpin daily nursing perform, and explores the way felony and moral facets of kid's nursing differs from these of adults.
All of the details you would like, correct at your fingertips! easy access to crucial drug details for pediatric sufferers is obtainable with the moveable, pocket-sized Delmar's MINI consultant TO PEDIATRIC medications.
With accompanying software program! Clinicians deal with loads of info - on different bits of paper and of their heads. This e-book is ready larger how one can deal with and comprehend quite a lot of scientific info. Following on from his flooring breaking publication, comparing the tactics of Neonatal in depth Care, Joseph Schulman has produced this eminently readable consultant to sufferer facts research.
- Wong’s Nursing Care of Infants and Children
- Fenichel's Clinical Pediatric Neurology. A Signs and Symptoms Approach
- Rudolph’s Pediatrics
- Making Better Drugs for Children with Cancer
Additional info for Cancer in Children: Clinical Management (Oxford Medical Publications)
Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61, 703â 8. 15. Vecht CJ, Wagner GL, Wilms EB (2003). Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2, 404â 9. 16. Boddy AV, Ratain MJ (1997). Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res 3, 1025â 30. 17. McLeod HL, Krynetski EY, Relling MV, Evans WE (2000). Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
Other alkylating agents that have a prominent role in paediatric oncology are cyclophosphamide, ifosfamide, melphalan, busulfan, thiotepa, and nitrosoureas such as carmustine (BCNU) and lomustine (CCNU). All these agents generate cross-links between or within the two DNA strands. The methylating agents, such as procarbazine, dacarbazine (DTIC), and the recent drug temozolomide, alter DNA but do not generate cross-links. The alkylating agents physically alter DNA. They may induce mutations and secondary malignancies such as myelodysplasia.
Docetaxel, a semisynthetic taxane, may have activity against selected paediatric solid tumours. Two phase I trials of docetaxel have been completed in children with refractory solid tumours. In the initial trial, docetaxel was administered every 21days. The MTD was 65 mg/m2 in heavily pretreated patients and 125 mg/m2 in less heavily pretreated patients. v. every 21 days) in children with refractory solid tumours was completed. Preliminary observations include activity in patients with Ewing sarcoma and osteosarcoma.